Innovera Life Science Fund

Innovestor Life Science Fund is a €90 million venture capital fund based in Helsinki, Finland, dedicated to early-stage investments in the life sciences and health sectors across the Nordics and Baltics. Launched in 2022, the fund focuses on breakthrough innovations in drug development and digital health that address significant unmet medical needs with global potential. The fund typically invests from pre-seed to Series A stages, with initial ticket sizes ranging from €250,000 to €3 million. Its portfolio includes high-impact companies such as Actithera, Tribune Therapeutics, and NEUmiRNA, often co-investing with major international venture capital firms and pharmaceutical partners to drive scientific breakthroughs toward clinical validation.